{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:56:26Z","timestamp":1789473386285,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2016-01675"],"award-info":[{"award-number":["2016-01675"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2017\u201301330"],"award-info":[{"award-number":["2017\u201301330"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","award":["ALF20160074"],"award-info":[{"award-number":["ALF20160074"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bond Life Sciences","award":["DU108"],"award-info":[{"award-number":["DU108"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TR002345"],"award-info":[{"award-number":["TR002345"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AI076119"],"award-info":[{"award-number":["AI076119"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["GM118012"],"award-info":[{"award-number":["GM118012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/jac\/dky256","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T19:08:59Z","timestamp":1528484939000},"page":"2721-2728","source":"Crossref","is-referenced-by-count":14,"title":["Antiretroviral potency of 4\u2032-ethnyl-2\u2032-fluoro-2\u2032-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes"],"prefix":"10.1093","volume":"73","author":[{"given":"Duncan T","family":"Njenda","sequence":"first","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden"},{"name":"Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambhu G","family":"Aralaguppe","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalendra","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden"},{"name":"Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA"},{"name":"Bond Life Sciences Center, University of Missouri, Columbia, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Rao","sequence":"additional","affiliation":[{"name":"Bond Life Sciences Center, University of Missouri, Columbia, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"S\u00f6nnerborg","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden"},{"name":"Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan G","family":"Sarafianos","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA"},{"name":"Bond Life Sciences Center, University of Missouri, Columbia, MO, USA"},{"name":"Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal","family":"Neogi","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"key\n\t\t\t\t20180921035211_dky256-B1","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3018(16)30087-X","article-title":"Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132015: the Global Burden of Disease Study 2015","volume":"3","author":"Wang","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180921035211_dky256-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t20180921035211_dky256-B3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3851\/IMP2982","article-title":"Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results","volume":"21","author":"Floris-Moore","year":"2016","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180921035211_dky256-B4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180921035211_dky256-B5","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180921035211_dky256-B6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180921035211_dky256-B7","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180921035211_dky256-B8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180921035211_dky256-B9","doi-asserted-by":"crossref","first-page":"35681","DOI":"10.1074\/jbc.M109.036616","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor","volume":"284","author":"Michailidis","year":"2009","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180921035211_dky256-B10","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation-defective RT inhibitor 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180921035211_dky256-B11","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1128\/AAC.00723-12","article-title":"Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine in vitro and in vivo","volume":"56","author":"Murphey-Corb","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B12","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.05036-14","article-title":"Oral administration of the nucleoside EFdA (4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque","volume":"59","author":"Stoddart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B13","volume-title":"IAS","author":"Matthews","year":"2017"},{"key":"key\n\t\t\t\t20180921035211_dky256-B14","doi-asserted-by":"crossref","first-page":"65.","DOI":"10.1186\/1742-4690-10-65","article-title":"Hypersusceptibility mechanism of tenofovir-resistant HIV to EFdA","volume":"10","author":"Michailidis","year":"2013","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180921035211_dky256-B15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180921035211_dky256-B16","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1128\/AAC.00283-13","article-title":"Evaluation of combinations of 4\u2019-ethynyl-2-fluoro-2\u2019-deoxyadenosine with clinically used antiretroviral drugs","volume":"57","author":"Hachiya","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B17","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/JVI.01349-08","article-title":"Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1","volume":"83","author":"Coutsinos","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180921035211_dky256-B18","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1128\/AAC.01151-15","article-title":"Characterization of HIV-1 resistance to tenofovir alafenamide in vitro","volume":"59","author":"Margot","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B19","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(16)00023-0","article-title":"Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden","volume":"3","author":"Haggblom","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180921035211_dky256-B20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dku365","article-title":"HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir\/ritonavir","volume":"70","author":"Sutherland","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B21","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180921035211_dky256-B23","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1128\/AAC.00648-12","article-title":"Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine","volume":"56","author":"Balamane","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B24","doi-asserted-by":"crossref","first-page":"20035.","DOI":"10.7448\/IAS.18.1.20035","article-title":"Subtype-independent near full-length HIV-1 genome sequencing and assembly to be used in large molecular epidemiological studies and clinical management","volume":"18","author":"Grossmann","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180921035211_dky256-B25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(10)70186-9","article-title":"Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease","volume":"11","author":"Tebit","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180921035211_dky256-B26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001726","article-title":"Ex vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV-1 non-B subtypes","volume":"32","author":"Neogi","year":"2018","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180921035211_dky256-B27","doi-asserted-by":"crossref","first-page":"38110","DOI":"10.1074\/jbc.M112.398180","article-title":"Biochemical mechanism of HIV-1 resistance to rilpivirine","volume":"287","author":"Singh","year":"2012","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180921035211_dky256-B28","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/AAC.01152-15","article-title":"In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate","volume":"59","author":"Callebaut","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B29","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1081\/NCN-100002495","article-title":"Purification of PMPA amidate prodrugs by SMB chromatography and x-ray crystallography of the diastereomerically pure GS-7340","volume":"20","author":"Chapman","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"key\n\t\t\t\t20180921035211_dky256-B30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B31","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2, 6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t20180921035211_dky256-B32","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","article-title":"Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants","volume":"47","author":"Das","year":"2004","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t20180921035211_dky256-B33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/aid.1992.8.145","article-title":"Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug","volume":"8","author":"Grob","year":"1992","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180921035211_dky256-B34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.04215-14","article-title":"Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors","volume":"59","author":"Basson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B35","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/QAI.0000000000001285","article-title":"HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa","volume":"75","author":"Kityo","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180921035211_dky256-B36","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/QAD.0b013e328346269f","article-title":"Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance","volume":"25","author":"Neogi","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180921035211_dky256-B37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/dkv359","article-title":"Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries","volume":"71","author":"Neogi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035211_dky256-B38","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/JVI.02904-13","article-title":"The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity","volume":"88","author":"Xu","year":"2014","journal-title":"J Virol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/10\/2721\/25770392\/dky256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:39:36Z","timestamp":1661420376000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/10\/2721\/5057985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,7,24]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky256","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,7,24]]}}}